Navigation Links
Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
Date:8/10/2012

PRINCETON, N.J., Aug. 10, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the second quarter ending June 30, 2012.

Soligenix's revenues for the quarter ending June 30, 2012 were $762,851 as compared to $405,820 for the second quarter of 2011. The increase in revenues was related to increased reimbursable costs from the Company's ThermoVax™, Thermostability Technology Grant focused on a novel method of rendering aluminum salt adjuvanted vaccines stable at elevated temperatures. 

Soligenix's net loss for the quarter ending June 30, 2012 was $979,878 or $(0.09) per share, as compared to $1,931,317 or $(0.18) per share for the quarter ending June 30, 2011, representing a decreased loss of $951,143. This decrease is attributable to increased gross profit related to the ThermoVax™ grant and reduced spending resulting from termination of the Phase 3 clinical trial of orBec® in acute GI GVHD. 

Research and development expenses for the quarter ending June 30, 2012 were $500,980 as compared to $1,513,722 for the quarter ending June 30, 2011. This decrease of $1,012,742 is primarily attributable to reduced spending in connection with the Phase 3 clinical trial of orBec®. General and administrative expenses for the quarter ending June 30, 2012 were $627,218, compared to $475,377 for the quarter ending June 30, 2011. This increase of $151,841 is primarily attributable to a greater share of allocated salaries to general and administrative due to decreased research and development programs.

As of June 30, 2012, the Company's cash position was approximately $4,430,000 with working capital of approximately $3,630,000.   

Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "In the second quarter of 2012 we continued progre
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
2. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Officer, will present at the Stem Cell Meeting on ... 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... 2014 Arbor Pharmaceuticals, LLC. - Product ... Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product Pipeline ... Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Arbor Pharmaceuticals, LLC.,s, ... assessment by drug target, mechanism of action (MoA), ...
(Date:9/30/2014)... Sept. 30, 2014  According to their CEO, ... cancer clinical trials is going through a complete ... the work of the current clinical trial management ... ,next generation, clinical trials, which will ultimately drive ... The company has been recognized by the ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... Today GenVec, Inc. (Nasdaq: GNVC ) announced financial ... 2010.  For the year ended December 31, 2010, the Company ... share, compared with a net loss of $18.4 million, or ... GenVec ended the year with $35.2 million in cash, cash ...
... RIVER EDGE, N.J., March 10, 2011 Nephros, Inc. ... device company developing and marketing filtration products for therapeutic ... completion of its rights offering and private placement that ... to Nephros.  The aggregate net proceeds received by Nephros ...
Cached Medicine Technology:GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 2GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 3GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 4GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 5GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 6GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 7GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 8Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 2Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 3Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 4
(Date:10/1/2014)... for holiday gift ideas? Éminence Organic Skin Care, the leader ... holiday season. Starting October 1st 2014, new spa gift sets ... Choose from two luxury skin care gift sets made from ... or to deliver whole body beauty. , The luxurious ... are formulated to suit all skin types and will tick ...
(Date:10/1/2014)... October 01, 2014 QueenBeeTickets.com is giving music ... the singer’s upcoming North American tour, which has him traveling ... come. , Click here to view the selection ... performer’s newest album, is due to come out on October ... shortly thereafter. Bob Seger concert tickets are available for shows ...
(Date:9/30/2014)... no genetic evidence that high levels of vitamin D ... Some previous research had suggested that elevated levels ... diabetes, raising the possibility of a link between vitamin ... this study, British researchers investigated the association between diabetes ... control blood levels of vitamin D. They found no ...
(Date:9/30/2014)... damaging "brain tsunamis" in injured patients without opening ... reality, thanks to pioneering research at the University ... team, led by Jed Hartings, PhD, research associate ... UC College of Medicine, has shown that spreading ... like tsunami wavescan be measured by the placement ...
(Date:9/30/2014)... Symposia will convene the first conference of its 2014-2015 ... Series on "The Modes of Action of Vaccine ... the conclusion of the Grand Challenges Meeting for that ... Keystone Symposia Global Health Series, supported by the Bill ... awards for 36 investigators from developing countries to attend. ...
Breaking Medicine News(10 mins):Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 3Health News:Bob Seger Presale Tickets: QueenBeeTickets.com Delights Fans with Discounted Tickets for All 20 Stops on Seger’s “Ride Out” Tour with The Silver Bullet Band 2Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2
... neck pain by spine manipulation appears of little use as ... in the UK to relieve many different types of pain,// ... ,When 16 studies were reviewed it was concluded ... is effective for treating any medical problem. ...
... member of the parliament belonging to the Papua New Guinea parliament ... virus//. He will be the first person in the country to ... unnamed MP could be jailed under a 2003 law that made ... Nation newspaper in Papua New Guinea reported. ,The paper ...
... became known that they had cheated the Medicare by more ... were not mandated and hence was never conducted. ... of the illegal scheme from 1997 to 2005. He and ... beneficiaries and introducing them to several doctor’s and medical labs ...
... (FSA), that the daily intake of salt should be limited to ... mention the amount of salt content in their food labels. A ... either side. ,A public awareness watchdog for Foodstuffs set ... salt in a lot of food products. This is done for ...
... common man that how official failings led to a man ... history of violence. Stuart Robertson was killed by James Smith, ... in October 2004. This report mainly gives us an insight ... , There was a failure to respond adequately ...
... the first of its kinds study conducted by the ... Communications Research (CECCR) found// that Women suffering from breast ... given the opportunity to participate in online support groups. ... to ,openly express themselves trying to make sense of ...
Cached Medicine News:Health News:Research demystifies treatment by manipulation of spine by chiropractors in the UK 2Health News:Salt & Its Intake Causes a Strong debate In UK 2Health News:Study Finds Online Support Groups Emotionally Benefit Women Suffering From 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: